Short-sellers and hedge funds may be shadowy, but sometimes they are the smartest guys in the room. They've done their homework, and they're willing to bet their capital against the crowd -- an investing strategy that can be as lucrative as it is contrarian.

On Motley Fool CAPS, we've also got leading analysts who find the chinks in a company's armor and correctly call its fall. Our "Underdogs" have earned 100 or more CAPS points by correctly predicting that one or more stocks would underperform the market. However, we're going to focus on the stocks these top members expect will outperform the market. If these CAPS investors have scored big by correctly predicting which stocks will fail, it may be worth our while to see which others they think will succeed.


Member Rating


CAPS Rating
(out of 5)



3-D Systems (Nasdaq: TDSC)




Boeing (NYSE: BA)




SuperGen (Nasdaq: SUPG)


Not every short sale goes as planned, making shorting a risky proposition. Stock prices can be irrational longer than you have money to stay in the game. So don't use this as a list of stocks to sell or buy -- just the launching pad for further research.

Underdogs still wag their tails
The movie Piranha 3-D might not have been Academy Award material, but if you could print out one of those flesh-eating fish on your home computer that would be really cool. 3-D Systems is looking to expand the capabilities of home 3-D printing systems and recently unveiled a line of consumer color printers that start at under $1,300.

Surprisingly, this is actually an active space with a number of players looking to capitalize on what Hewlett-Packard (NYSE: HPQ) could be a multi-billion industry. It teamed up last year with 3-D Systems rival Stratasys (Nasdaq: SSYS), but with its systems going for tens of thousands of dollars, the value of 3-D Systems low-priced models has the potential to really have the sector take off.

CAPS member Downhill28 thinks the growing popularity of 3-D technology will allow 3-D Systems to be a big winner.

If you look at the 3-D products coming out and the speed that they are coming out and how much it influences little things like youtube videos to big things like cinemas, then it would be no surprise to me if 3-D Systems Corp outperforms the market.

Get some eye-popping opinions by checking out the 3-D Systems CAPS page and adding your own thoughts to the growing body of interest.

Right to stop
Tired of the machinists union in Washington going on strike four times in 10 years and costing it billions of dollars in lost business, Boeing opted to open a second manufacturing plant in right-to-work state South Carolina that has already hired 1,000 workers. The National Labor Relations Board, which is supposed to impartially oversee the rights of workers and business in negotiations, has filed a complaint against the plane maker saying the decision to open the second facility was illegal because it was non-union.

The NLRB's decision to file a complaint is a departure from prior board practice, and from Supreme Court decisions. But Boeing isn't acquiescing and vows to fight, noting that not a single union job in its Puget Sound facility was affected by the new plant, and they note that they've actually expanded the workforce there by 2,000 employees.

If the administrative judge scheduled to hear the case this June decides in the union's favor, it will effectively give unions veto power over the right over Boeing or any manufacturer for that matter to move operations.

MajorBob04 notes plane orders are finally recovering, a situation that could be affected by whatever the court rules.

Airplane orders are finally recovering to pre-crisis levels. And the Paris air show is coming up in June-expect many new orders ...

Keep an eye on how the ruling develops by adding Boeing to the Fool's free portfolio tracker.

All aboard!
After agreeing to a merger with Astex Therapeutics and despite the potential for lucrative milestone payments from pharmaceutical giants Johnson & Johnson (NYSE: JNJ) and GlaxoSmithKline (NYSE: GSK), investors sent shares of SuperGen tumbling, doubting the wisdom of the move.

SuperGen says the new company will have seven drug candidates, including four that are in mid-stage testing or are getting ready to move into mid-stage development. Those large drug makers above and others are helping to develop three of those four drugs.

Even if there are doubts, 96% of the CAPS members rating the drug developer believe it will outperform the broad market averages. Add SuperGen to your watchlist to see how this merger develops.

There's no need to fear...
Underdogs often shine brightest with their backs against the wall. Still, it takes more than a few All-Star picks and a quick paragraph to make buy or sell decisions. Start your own research on these stocks on Motley Fool CAPS where your opinion can still save the day. While there, you can read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made, all from a stock's CAPS page.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.